U.S. equity markets on Thursday displayed considerable intraday dispersion, with leaders and laggards spanning mega-cap technology names down to speculative small-caps. Cisco Systems was among the strongest performers, while Qualcomm was among the larger decliners. Several mid-cap companies moved on company-specific developments such as orders, financing and earnings, and small-caps reacted to mixed operational news and trial outcomes.
Mega-Cap Movers (Market Cap $200B+)
- Cisco Systems (CSCO) +13.02%
- Avago Technologies (AVGO) +4.46%
- Nvidia Corp (NVDA) +3.9%
- Oracle Corp (ORCL) +2.98%
- Palantir Technologies Inc (PLTR) +2.85%
- IBM (IBM) +2.13%
- Intel Corp (INTC) -3.52% - note: Intel partners with McLaren Racing as compute provider
- SanDisk Corp-Exch (SNDK) -3.23%
- Alibaba-exch (BABA) -2.75%
- Qualcomm Inc (QCOM) -5.38%
Large-Cap Movers (Market Cap $10B-$200B)
- New Providence Acquisition Corp N (ASTS) +11.05%
- Nova Measuring In (NVMI) +10.66%
- Forgent Power Solutions Inc (FPS) +10.19% - noted as rising after a strong revenue beat and raised guidance
- Yandex (NBIS) +7.71%
- Viking Holdings (VIK) +7.64% - reported to have beaten first quarter estimates as revenue jumped 18%
- Coinbase Global (COIN) +7.05%
- MicroStrategy Inc (MSTR) +6.91%
- World Wrestling Entertainment (TKO) +6.76%
- Applied Opt (AAOI) -7.66%
- Pershing Square Inc (PS) -10.94%
Mid-Cap Movers (Market Cap $2B-$10B)
- POET Tech NAQ (POET) +38.97% - reported to have secured a $50M order from Lumilens
- Ondas (ONDS) +28.33%
- Fermi America LLC (FRMI) +24.08% - reported a $189M Q1 loss and secured $785M in financing
- Redwire (RDW) +23.56%
- Accelerant Holdings Ltd (ARX) +19.1% - shares rose after beating Q1 estimates and issuing upbeat guidance
- StubHub Inc (STUB) +16.82% - surged on a revenue beat and profit growth
- Ekso Bionics Holding (CHRN) +12.9%
- Lightwave Logic Inc (LWLG) -17.21% - fell despite noted market expansion, on modest revenue
- Doximity (DOCS) -25.69% - tumbled after missing fourth quarter earnings
- Intel Corp (INTC) -3.05% (also listed among mega-caps)
Small-Cap Stock Movers (Market Cap $300M-$2B)
- Purecycle Technologies Holdings (PCT) +20.29%
- Hyperliquid Strategies (PURR) +18.29%
- Retail Value (RVI) -19.02%
- Aeluma (ALMU) -19.8%
- Innovative Soluti (ISSC) -19.33%
- Adagio Therapeutics (IVVD) -20.75%
- Methode Electronics Inc (MEI) -23.65%
- Regenxbio Inc (RGNX) -37.3% - the company is noted as gaining 4% on a Duchenne trial win despite an earnings miss
- Dreamland Ltd (TDIC) -91.84%
Across market-cap segments, the drivers cited in company notes include revenue beats, raised guidance, large customer orders, clinical trial outcomes, and significant financings. Several names that reported operational setbacks or earnings misses saw sharp share-price declines, while companies with order announcements or financing secured saw outsized gains.
Market context and takeaways
- Technology and semiconductor names feature prominently among both advancers and decliners, reflecting concentrated activity within those sectors.
- Biotech and clinical-stage issuers are moving on trial-related news, with at least one company noted for a trial win paired with an earnings miss.
- Smaller issuers continue to show elevated volatility tied to discrete corporate events: financing announcements, large orders and earnings beats or misses.
Notable company-specific points cited in the session
- Intel announced a partnership with McLaren Racing to serve as a compute provider - the stock was lower in the session.
- POET Technologies was reported to have received a $50 million order from Lumilens, a development linked to a very large intraday gain.
- Fermi America disclosed a substantial first-quarter loss alongside a sizeable financing arrangement, both noted in its market move.
- Forgent Power is described as having posted a strong revenue beat and raised guidance, coinciding with a double-digit share increase.
Investors reacted to an array of company-level developments rather than a single dominant market narrative. The session illustrated how earnings outcomes, clinical results, major orders and capital raises can drive meaningful intraday re-pricing across market capitalizations.